COMMUNIQUÉS West-GlobeNewswire

HNL Lab Medicine Begins Subtyping Positive Flu A Samples for H5N1 Avian Influenza
20/02/2025
ALLENTOWN, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- In response to updated recommendations from the Centers for Disease Control and Prevention, HNL Lab Medicine will begin subtyping all positive influenza A samples from [...]
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
20/02/2025
Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, immune disorders and [...]
NanoNewron and its Research to Advance the Treatment of Alzheimer’s Disease are Featured by Rutgers University Newsletters and on Rutgers Today
20/02/2025
UNION, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- NanoNewron, LLC (“NanoNewron” or the “Company”), a pioneering biotechnology company developing innovative, humanized biologics that cross the blood-brain barrier (BBB) to [...]
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO
20/02/2025
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20 th Congress of ECCO NANTES, France – February 20, 2025, 6:00pm [...]
OSE Immunotherapeutics présente des données précliniques positives sur l'anti-IL-7 récepteur Lusvertikimab en combinaison dans la colite chronique En présentation orale au 20ème congrès de l’ECCO
20/02/2025
OSE Immunotherapeutics présente des données précliniques positives sur l'anti-IL-7 récepteur Lusvertikimab en combinaison dans la colite chronique En présentation orale au 20 ème congrès de l’ECCO Nantes, France, le 20 [...]
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy
20/02/2025
- Based on alignment gained with FDA under the Regenerative Medicine Advanced Therapy (RMAT) designation, Neurona plans to conduct the Phase 3 EPIC ( EPI lepsy C ell therapy) trial as the primary basis for a future NRTX [...]
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
20/02/2025
NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE [...]
Egetis Therapeutics to Feature MCT8 Deficiency on Behind the Mystery Airing on Lifetime in Honor of Rare Disease Day
20/02/2025
STOCKHOLM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX), an innovative pharmaceutical company specializing in late-stage development and [...]
Acentra Health Employees Provide Over 3,000 Hours of Volunteer Work to Promote Healthier Communities
20/02/2025
Employee-led corporate social responsibility campaigns contributed over $332,000 in global support to improve access to food, education, and healthcare services MCLEAN, Va., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Acentra [...]
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split
20/02/2025
WASHINGTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today [...]
Serenity Medical Announces Clinical Publication of First Prospective Multicenter Trial of the River™ Stent, a Novel Venous Sinus Stent for Treating Idiopathic Intracranial Hypertension (IIH)
20/02/2025
Publication in the Journal of NeuroInterventional Surgery Reports Outcomes for Treatment of IIH Patients Who Are Refractory or Intolerant to Medications HARRISON, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Serenity Medical [...]
Anbio Biotechnology Announces Closing of Initial Public Offering
20/02/2025
Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro [...]
Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock
19/02/2025
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”) a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that [...]
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
19/02/2025
SAN FRANCISCO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/02/2025
NOVATO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare [...]
ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March
19/02/2025
PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and select members of [...]
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
19/02/2025
CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational [...]
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025
19/02/2025
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today [...]
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference
19/02/2025
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at TD Cowen's [...]

Pages